Perphenazine is the mid-potency FGA that the CATIE trial put back on the clinical map. For years before CATIE, the assumption was that all SGAs were uniformly superior to all FGAs. CATIE — the Clinical Antipsychotic Trials of Intervention Effectiveness, published in 2005 — directly tested that assumption by comparing perphenazine to olanzapine, risperidone, quetiapine, and ziprasidone.
- Class
- Mid-potency first-generation antipsychotic
- Mechanism
- D2 antagonism with moderate H1, M1 activity
- Typical dose
- 8-64 mg/day in divided doses
- Half-life
- ~9-12 hours
- FDA indications
- Schizophrenia, severe behavioral problems
- Key adverse effects
- EPS (intermediate level), sedation, anticholinergic effects, weight gain, hyperprolactinemia
Black box: Increased mortality in elderly patients with dementia-related psychosis
CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness, 2005) found perphenazine comparable to most SGAs in efficacy and overall tolerability — challenging the assumption that SGAs were superior. Modern niche: cost-effective FGA option with moderate tolerability profile.
The result was instructive. Perphenazine performed comparably to most SGAs on overall effectiveness and discontinuation rates. It was not the worst-performing arm; in some measures it was competitive with the best. The trial challenged the reflexive preference for newer antipsychotics and surfaced the fact that within-class differences among SGAs can be larger than the FGA-SGA distinction.
Perphenazine is a mid-potency FGA that earned renewed attention as the FGA comparator in the CATIE trial, performing comparably to several SGAs.
Mechanism note: Perphenazine's mid-potency profile and its CATIE-trial performance make it the FGA most often cited as still clinically and economically reasonable.
The pharmacology is mid-potency D2 antagonism with moderate H1 and M1 activity. The clinical profile sits between haloperidol (more EPS, less sedation) and chlorpromazine (more sedation, less EPS). For many patients, the balance is acceptable.
Modern niches: cost-effective FGA when SGA expense or formulary restriction is the issue. Patient with established response. Patient for whom SGA metabolic effects are particularly problematic — perphenazine has minimal metabolic burden compared to olanzapine or quetiapine. The patient who needs an antipsychotic but is already obese, diabetic, or hyperlipidemic might be better served by perphenazine than by an SGA that would worsen those parameters.
- Cost
- Generic: ~$10-30/month.
- Generic status
- Generic for decades.
- Formulary typical
- Tier 1 generic.
- Access friction
- Minimal. Smaller pharmacies may not stock.
Prescriber tip: CATIE-validated cost-effective option. Useful for the patient who can't accept SGA metabolic burden or where cost is the constraint.
The CATIE-era lesson generalizes: choose antipsychotics based on patient-specific factors — metabolic risk, EPS sensitivity, sedation needs, prior response, cost — rather than on a reflexive class preference. Perphenazine deserves a place in the consideration set.